Fluoxetine for Bulimia Nervosa: Titration and Duration
For bulimia nervosa, fluoxetine should be initiated at 60 mg daily in the morning without gradual titration, and continued for at least 52 weeks after achieving response to prevent relapse. 1, 2
Titration to 60 mg
The FDA-approved dose for bulimia nervosa is 60 mg/day, administered as a single morning dose. 2 Unlike depression or OCD where you start at 20 mg, the target dose for bulimia is 60 mg from the outset.
Titration Options:
Direct initiation at 60 mg/day: The FDA label states "the recommended dose is 60 mg/day, administered in the morning," without requiring gradual titration. 2
Gradual titration over several days: The FDA label notes "for some patients it may be advisable to titrate up to this target dose over several days," but does not specify an exact schedule. 2
Practical approach: If tolerability is a concern, you can start at 20 mg and increase to 40 mg after 3–7 days, then to 60 mg after another 3–7 days, reaching the target dose within 1–2 weeks maximum. 3
The key distinction is that 60 mg is the only dose proven effective in controlled trials—the 20 mg dose was NOT statistically superior to placebo for reducing binge-eating and vomiting frequency. 2, 4
Duration of Treatment
Acute Phase (Initial 8 Weeks):
Response is defined as ≥50% reduction in vomiting frequency during at least one of the two weeks preceding the 8-week assessment. 5
Approximately 65% of patients achieve response criteria after 8 weeks at 60 mg/day. 5
Maintenance Phase (After Response):
Continue fluoxetine 60 mg/day for at least 52 weeks (one full year) after achieving response. 2, 5
Systematic evaluation demonstrated that continuing fluoxetine 60 mg/day for up to 52 weeks in responders significantly improved outcomes and decreased relapse likelihood compared to placebo. 5
Fluoxetine-treated patients exhibited significantly longer time to relapse than placebo-treated patients during the 52-week maintenance phase. 5
Patients should be periodically reassessed to determine ongoing need for treatment, but premature discontinuation increases relapse risk substantially. 2
Long-Term Considerations:
Bulimia nervosa is a chronic condition, making long-term continuation reasonable for responding patients beyond 52 weeks. 2
Dosage adjustments should maintain patients on the lowest effective dose, though 60 mg/day is the established therapeutic dose for bulimia. 2
Evidence Base
Only the 60 mg dose was statistically significantly superior to placebo in reducing binge-eating and vomiting frequency in controlled trials. 2, 4 In the pivotal 8-week multicenter trial of 387 patients, fluoxetine 60 mg/day proved superior to both placebo and the 20 mg/day dose. 4
The 16-week extension study confirmed sustained efficacy and safety of 60 mg/day, with significantly greater reductions in vomiting (F1, 360 = 14.73, P < 0.0001) and binge-eating episodes (F1, 360 = 14.39, P = 0.0002) compared to placebo. 6
Common Pitfalls to Avoid
Underdosing: Using 20 mg or 40 mg daily is inadequate—these doses lack proven efficacy for bulimia nervosa. 2, 4
Premature discontinuation: Stopping before 52 weeks dramatically increases relapse risk, as the maintenance benefit is well-established. 5
Delaying target dose: Prolonged titration over weeks delays therapeutic benefit—reach 60 mg within days to 1–2 weeks maximum. 2
Monotherapy expectations: Fluoxetine is most effective when combined with cognitive-behavioral therapy or structured self-help interventions. 1, 7, 8
Special Populations
Hepatic impairment: Use lower or less frequent dosing. 2
Elderly patients: Consider lower or less frequent dosing. 2
Renal impairment: No routine dosage adjustment necessary. 2
Safety Monitoring
Common adverse events at 60 mg include insomnia, nausea, asthenia, and tremor, but discontinuation rates due to adverse events do not differ significantly from placebo. 4
Monitor for suicidal ideation, particularly during initial treatment and dose changes. 2
Fluoxetine's long half-life (1–3 days for parent compound, 4–16 days for norfluoxetine) means steady-state is not reached for 5–7 weeks, and discontinuation symptoms are minimized compared to shorter-acting SSRIs. 3, 2